DataMEDS SI Cuts Costs to Focus on Tumor Diagnostic Test Expansion
Pittsburgh, Tuesday, 13 October 2026.
DataMEDS SI restructured operations on October 13, 2026, pivoting to commercialize its ChemoFx cancer assay, a test backed by a repository of over 70,000 tumor samples.
Strategic Realignment and Cost Controls
DataMEDS SI (NASDAQ:MEDS) announced a major operational update on October 13, 2026, detailing targeted cost reduction measures and a strategic pivot toward the commercialization of its proprietary ChemoFx platform [1]. The health IT firm stated it has realigned its remaining workforce to focus directly on securing enterprise agreements with hospital systems, health maintenance organizations, and regional cancer centers [1]. This restructuring follows the company’s acquisition of Helomics Corporation on September 11, 2026, which incorporated the Predictive Oncology Cancer Biomarker Super Intelligence division into its portfolio [1][3]. The company aims to streamline operating efficiency while leveraging the CLIA-certified laboratory capabilities acquired through the transaction [1].
Operational Focus
Management indicated that corporate management workforce reductions were executed to shift resources toward commercializing the ChemoFx diagnostic lab test for gynecologic cancers [1]. The test, which has been commercially available in the U.S. since 1997, utilizes CPT codes 81535 and 81536 for billing [1][2]. DataMEDS SI plans to leverage a repository of over 70,000 de-identified tumor samples, including approximately 20,000 ovarian cancer samples, to support research collaborations and therapeutic target discovery [1]. The strategic focus remains on bolstering revenue streams through the integration of the test into hospital and cancer center programs [1].
Humana Medicaid Coverage
This operational pivot follows an announcement on October 12, 2026, that Helomics received a Medicaid coverage determination from Humana for the ChemoFx Assay in gynecologic cancers [2][3]. The coverage policy, identified as HUM-SC-2240-003, became effective on July 22, 2026, allowing eligible Medicaid members to access the test under specific clinical settings [2][3]. Covered indications include initial biopsy or surgery, recurrent or treatment-refractory cancer, and cases where recommended treatment is not tolerated [3][4]. The company noted that the laboratory is positioned to support additional volume as coverage grows, citing prior investments in laboratory automation [2][3].
Coverage Details
The ChemoFx Assay is a laboratory-developed test that measures how a patient’s live tumor cells respond to chemotherapy agents, though it currently lacks FDA clearance or approval [3][4]. Coverage is not universal across all Humana plans, but the determination provides a pathway for reimbursement tied to CPT codes 81535 and 81536 [3][4]. Economic studies cited by the company suggest cost-effectiveness, with an incremental cost-effectiveness ratio of $6,206 per life-year saved for recurrent epithelial ovarian cancer [3]. DataMEDS is preparing additional clinical utility data analyses for peer-review publication to support label expansion beyond gynecologic cancers [1][3].
Market Reaction and Financial Context
Following the coverage news, market participants observed significant volatility in DataMEDS AI shares, with reports of a surge in premarket trading on October 12, 2026 [5][6]. While one report noted a closing price of $2.96 on the preceding Friday, other data indicated premarket trading levels reaching $4.09, representing a substantial percentage increase calculated as 38.176 [4][5]. Short interest in the stock was reported near 20% of the float during this period, contributing to price movement [5]. The company has historically demonstrated high volatility, with a 52-week trading range reported between $0.82 and $73.00 [5].
Future Outlook
Looking ahead, DataMEDS SI intends to seek research collaborations using its tumor sample repository and proprietary organoid technology [1]. The company is also developing multiple proprietary platforms, including EinsteinRx AI and PharmacyChain, alongside a proposed transaction involving DataVault AI Inc. and other entities [1][3]. Management emphasized the goal of securing expanded coverage and reimbursement from Medicare and commercial plans while maintaining compliance with CLIA and state laboratory standards [3]. These initiatives aim to stabilize revenue streams following the operational restructuring announced on October 13, 2026 [1].